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Myeloproliferative disordersPrimary myelofibrosis (PMF) is a clonal myeloproliferative neoplasm whose severity and treatment com-
plexity are attributed to the presence of bone marrow (BM) fibrosis and alterations of stroma impairing
the production of normal blood cells. Despite the recently discovered mutations including the JAK2V617F
mutation in about half of patients, the primitive event responsible for the clonal proliferation is still
unknown. In the highly inflammatory context of PMF, the presence of fibrosis associated with a
neoangiogenesis and an osteosclerosis concomitant to the myeloproliferation and to the increase number
of circulating hematopoietic progenitors suggests that the crosstalk between hematopoietic and stromal
cells is deregulated in the PMF BM microenvironmental niches. Within these niches, mesenchymal stro-
mal cells (BM-MSC) play a hematopoietic supportive role in the production of growth factors and extra-
cellular matrix which regulate the proliferation, differentiation, adhesion and migration of hematopoietic
stem/progenitor cells. A transcriptome analysis of BM-MSC in PMF patients will help to characterize their
molecular alterations and to understand their involvement in the hematopoietic stem/progenitor cell de-
regulation that features PMF.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).SpecificationsOrganism/cell line/tissue Primary mesenchymal stromal cells from human
bone marrowSex Pathology sex independent
Sequencer or array type Agilent single color Oligo Microarray 4 ∗ 44k
Data format Agilent normalized matrix
Experimental factors Bone marrow from primary myelofibrosis patients
versus healthy donors (similar age)
Experimental features Adult (60–80 years old) primary BM-MSCs amplified
in vitro for 3 to 5 passages — GSE44426
Consent Helsinki consent
Sample source location France and Italia33, Paul BrousseHospital, Andre
. This is an open access article under1. Direct link to deposited data
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE44426.
1.1. Experimental design, materials and methods
The transcriptome of medullary stromal cells of patients suffering
from primary myelofibrosis was studied by Agilent Oligo microarray
technology. The primary myelofibrosis is a chronic myeloproliferative
syndrome. To invest the role of bone marrow stroma in the pathophys-
iology of this disease, we isolated primary cultured of bone marrow
stromal cells from these patients. The osteo-medullary biopsies for the
diagnosis of the disease were implanted in DMEM medium with 10%
fetal calf serum. Stromal cells during their proliferation adhere to plastic
and they were trypsinized between each passage (3–5 passages) when
cultures came to confluence. These steps were performed to eliminatethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2 C. Martinaud et al. / Genomics Data 5 (2015) 1–2the remaininghematopoietic cell fraction in these cultures. A cytometric
control was carried out on the cells prior to performing molecular
biology experiments. CD105, CD73 and CD90 marker positivity was
verified to validate the mesenchymal cell phenotype. The negativity of
the CD45 marker was also carried out to prove the absence of residual
hematopoietic cells in culture. Each culture of mesenchymal stromal
cell is isolated from the bone marrow of an individual. In total, the
bone marrow samples were studied individually from 6 healthy do-
nors (6 controls: GSM1084994, GSM1084995, GSM1084996,
GSM1084997, GSM1084998, GSM1084999) and from 6 patients
with primary myelofibrosis (6 PMF: GSM1085000, GSM1085001,
GSM1085002, GSM1085003, GSM1085004, GSM1085005).
Concerning the enrollment of control samples: subjects are negative
for alcohol abuse and HCV, HBV and HIV virus infections. The choice
of control subjects was conditioned by access to bone marrow from
subjects having a hip prosthesis surgery: indeed the subjects have
an average age similar to that of patients with primary myelofibrosis
(between 60 and 80 years). Each sample was treated individually for
the extraction of nucleic acids and the achievement of microarrays.
RNA was isolated using RNA extraction protocols (NucleoSpin RNA II,
Macherey-Nagel) on the Miltenyi plateform. RNA samples were
quality-checked via the Agilent 2100 Bioanalyzer (Agilent Technolo-
gies). Total RNA sample (1 μg) was used for linear T7-based amplifica-
tion. RNA samples were amplified and labeled using the Agilent Quick
Amp Labeling Kit/Low RNA Input Linear Amp Kit (Agilent Technolo-
gies). The hybridization procedure was performed using Agilent Gene
Expression Hybridization Kit (Agilent Technologies). Briefly, 1.65 μg
Cy3-labeled fragmented cRNA in hybridization buffer was hybridizedovernight (17 h, 65 °C) to Agilent Whole Human Genome Oligo Micro-
arrays 4 ∗ 44k using Agilent's in hybridization chamber. The fluores-
cence signals were detected using Agilent's Microarray Scanner
System (Agilent Technologies). The Agilent Feature Extraction Software
(FES) v9.1 was used to read out and process the microarray image files.
The software determines feature intensities including background sub-
traction. The signal intensities from single experiment raw data lists are
normalized by dividing the intensities values by their median. Normal-
ized data were accessible on public database: (GEO submission number
GSE44426, http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE44426), online on Jan. 10, 2015) [1,2].
Appendix A Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.gdata.2015.04.017.
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